求助文献全篇下载

baby00000003

Clinical case reports of injectable tissue-engineered bone for alveolar augmentation with simultaneous implant placement  @& @9 N. W  T  @% B
M. Ueda, Y. Yamada, R. Ozawa, Y. Okazaki
& \6 ]7 y6 x5 Z/ p5 s* RDOI: http://dx.doi.org/10.1016/j.prosdent.2005.05.019; h# P$ W( r. y6 O2 U

/ Y, r0 E7 z4 N% e3 G感谢各位老师的无私援助～

farui

Noteworthy Abstracts of the Current Literature0 M& y! X8 O1 F( i9 x& p, l5 v
Clinical case reports of injectable tissue-engineered bone for alveolar augmentation with simultaneous implant placement
6 p! Y. p4 Y" u5 D& x8 O- O( x1 H% Q" i2 `, H. H/ t- F2 `
    M. Ueda, Y. Yamada, R. Ozawa, Y. Okazaki4 c2 f9 q' ~" K+ V

" `* H5 L- e, V9 h+ x+ s% }" s9 Z Show more
. f" d9 L) E- G( X+ Y3 ^0 m' t( g' a4 t+ z( X2 C7 m4 c
        doi:10.1016/j.prosdent.2005.05.019
; C: U1 T1 D  C7 X# V8 b    Get rights and content
7 D( x* }& x8 q. O8 I& s
$ l$ _" X. t$ F) W" S$ C% X2 ^% xThis clinical study was undertaken to evaluate the use of tissue-engineered bone, mesenchymal stem cells, platelet-rich plasma, and beta-tricalcium phosphate as grafting materials for maxillary sinus floor augmentation or onlay plasty with simultaneous implant placement in six patients with 3- to 5-mm alveolar crestal bone height. All 20 implants were clinically stable at second-stage surgery and 12 months postloading. A mean increase in mineralized tissue height of 7.3 ± 4.6 mm was evident when comparing the pre- and postsurgical radiographs. Injectable tissue-engineered bone provided stable and predictable results in terms of implant success.—Reprinted with permission of Quintessence Publishing.
/ y7 f9 X4 @# d' a+ A( S
8 f! a+ r- H) M8 u5 j1 T整个PDF就这一点内容

baby00000003

回复 farui 的帖子
9 G: ]6 F, G$ x) H7 {5 j$ x# Q4 N" f; l$ j, w
那必然不是呀～